anne vanlent appointed to aegerion pharmaceuticals board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street anne vanlent appointed to aegerion pharmaceuticals board of directors globenewswire apr    am edt cambridge mass april   globe newswire  aegerion pharmaceuticals inc nasdaqaegr a biopharmaceutical company dedicated to the development and commercialization of innovative lifealtering therapies for patients with debilitating often fatal rare diseases today announced the appointment of anne m vanlent to its board of directors effective april   ms vanlent will serve as chair of the audit committee ms vanlent is currently the president of amv advisors an advisory firm which she founded in  to provide corporate strategy and financial consulting services to emerging growth life science companies previously ms vanlent was executive vice president and chief financial officer of barrier therapeutics inc prior to that she was executive vice president portfolio management for sarnoff corporation a multidisciplinary research and development firm earlier in her career she served as senior vice president and chief financial officer of the liposome company inc ms vanlent also currently serves as a member of the board of directors of integra lifesciences and tranzyme pharma where she serves as audit chair she has previously served as a member of the board of directors of penwest pharmaceuticals and istat corporation anne brings industry experience strategic corporate leadership and deep financial knowledge to our board at a pivotal time for the company said david scheer chairman of the board marc d beer chief executive officer of aegerion added we welcome anne as a valued addition to our board as we seek to become a leading biotechnology company focused on developing and commercializing therapies for rare diseases annes guidance will be invaluable through these early days of commercial launch and beyond anne vanlent also added aegerion has established a bestinclass board and i am pleased to have the opportunity to contribute to the companys growth and ongoing success in a meaningful way i am excited to be a part of a patientcentric organization which has begun the journey of helping people with hofh if you liked this article you might like  stocks insiders love right now insiders at these companies are scooping up shares of their own stock lately roberto pedone sep    pm edt  stocks under  making big up moves when a stock makes a largepercentage move it is often just the start of a new major trend  a trend that can lead to huge profits roberto pedone aug    am edt  stocks under  set to soar these under stocks are within range of triggering breakout trades roberto pedone jun    pm edt wall street loses gains after feds unsurprising june call the results of the federal reserves june meeting were not a surprise the central bank left rates unchanged just as wall street expected keris alison lahiff jun    pm edt trending gm may slash six car models to combat slumping sales avoid plant layoffs  reasons dying sears had to strike a deal with the ruthless amazon dont sleep on general electrics cheap stock price starbucks has an alarming problem that even its fans must admit has to be fixed  and soon  foods to avoid if you have high cholesterol advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers anne m vanlent is no longer serving in their board position at novelion therapeutics inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology see more news on health care anne m vanlent is no longer serving in their board position at novelion therapeutics inc email linkedin facebook google tweet reddit permalink jul    relsci data update board and executive moves background information anne m vanlent » founder at amv advisors career amv advisors barrier therapeutics inc technology compass group llc boards applied genetic technologies corp aviragen therapeutics inc aegerion pharmaceuticals inc education mount holyoke college in the news ocera therapeutics appoints biopharmaceutical veteran willard dere md to board of directors october    •  globenewswire applied genetic appoints new board member august    •  marketline newswire agtc appoints anne m vanlent to its board of directors august    •  globenewswire anne m vanlent » founder at amv advisors career • amv advisors • barrier therapeutics inc • technology compass group llc boards • applied genetic technologies corp • aviragen therapeutics inc • aegerion pharmaceuticals inc education • mount holyoke college in the news ocera therapeutics appoints biopharmaceutical veteran willard dere md to board of directors  october    •  globenewswire applied genetic appoints new board member  august    •  marketline newswire agtc appoints anne m vanlent to its board of directors  august    •  globenewswire novelion therapeutics inc » novelion therapeutics inc develops and markets ocular products it is engaged in developing new standards of care for individuals living with rare diseases the company is headquartered in vancouver canada in the news novelion therapeutics to announce first quarter  financial results on may   may    •  globenewswire novelion therapeutics announces presentation at the bloom burton  co healthcare investor conference april    •  globenewswire metreleptin and lipodystrophy data presented at the annual meeting of the endocrine society april    •  globenewswire novelion therapeutics inc » novelion therapeutics inc develops and markets ocular products it is engaged in developing new standards of care for individuals living with rare diseases the company is headquartered in vancouver canada in the news novelion therapeutics to announce first quarter  financial results on may    may    •  globenewswire novelion therapeutics announces presentation at the bloom burton  co healthcare investor conference  april    •  globenewswire metreleptin and lipodystrophy data presented at the annual meeting of the endocrine society  april    •  globenewswire see more news on health care youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ vanlent anne m  the wall street transcript anne m vanlent anne m vanlent joined barrier therapeutics inc as executive vice president and chief financial officer in may  concurrent with the closing of the initial  million financing ms vanlent brings to barrier  years of senior management experience with both public and private emerging growth companies in healthcare and technology prior to joining barrier she was executive vice president portfolio management for sarnoff corporation where she directed sarnoff’s venture spinoff process and was in charge of all patent and licensing activities from the early s until joining sarnoff in  ms vanlent held senior management positions in or consulted for a number of emerging growth healthcare companies she served as chief financial officer for the liposome company inc now part of elan pharmaceuticals from  until  where she was involved with the its initial public offering as well as several other public and private financings she also served as evp and cfo for an early stage neuroscience company trophix pharmaceuticals inc which was purchased by allelix and consulted with several other private companies ms vanlent is a member of the board of directors of penwest pharmaceuticals and istat corporation she holds a bachelor of science degree from mount holyoke college in physics and did graduate work in biophysics related interviewsgeert cauwenbergh  barrier therapeutics incoctober   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google agtc appoints anne m vanlent to its board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       agtc agtc appoints anne m vanlent to its board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs gainesville fla and cambridge mass aug   globe newswire  applied genetic technologies corporation nasdaqagtc a biotechnology company conducting human clinical trials of adenoassociated virus aavbased gene therapies for the treatment of rare diseases today announced it has appointed anne m vanlent to the companys board of directors ms vanlent will replace bruce peacock on the board who had announced his intent to resign earlier this year “we thank bruce for his valuable service to agtc and wish him well on his future endeavors” said sue washer president and ceo of agtc we expect anne’s knowledge and experience in the healthcare industry coupled with her deep executive leadership and financial planning background to be valuable assets to the agtc board of directors and leadership team” said ms washer her established track record in providing strategic counsel to growing companies will support our ongoing efforts to advance our lead candidates for rare eye diseases and other inherited conditions ms vanlent founded and currently serves as president of amv advisors an advisory firm that provides corporate strategy and financial consulting services to emerging growth life science companies she is currently a director and chairperson of the audit committees of aegerion pharmaceuticals inc and ocera therapeutics inc and the lead independent director and chairperson of the audit committee of aviragen pharmaceuticals inc previously ms vanlent held executive roles with barrier therapeutics inc sarnoff corporation and the liposome company inc additionally she has served on the boards of onconova therapeutics integra life sciences holding corporation and penwest pharmaceuticals ms vanlent holds a bachelor of arts degree in physics from mount holyoke college “this is an exciting time for agtc and i look forward to working with the company’s executive leadership team and other board members to help fulfill the company’s mission to develop novel gene therapies to improve the quality of life for patients affected by rare inherited disorders” said ms vanlent about agtc agtc is a clinicalstage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases with an initial focus in ophthalmology agtcs lead product candidates are designed to treat inherited orphan diseases of the eye caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments agtcs product pipeline includes six named ophthalmology development programs across five targets xlinked retinoschisis xlrs xlinked retinitis pigmentosa xlrp achromatopsia wet agerelated macular degeneration and blue cone monochromacy two nonophthalmology programs alpha antitrypsin deficiency and adrenoleukodystrophy and agtc is continuing to develop early research studies in additional indications  the company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years agtc employs a highly targeted approach to selecting and designing its product candidates choosing to develop therapies for indications having high unmet medical need clinical feasibility and commercial potential agtc has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids promoters and expression cassettes as well as expertise in the formulation manufacture and physical delivery of gene therapy productsirpr contacts david carey ir or danielle lewis pr lazar partners ltd t   or   dcareylazarpartnerscom or dlewislazarpartnerscom corporate contacts larry bullock chief financial officer applied genetic technologies corporation t   lbullockagtccom stephen potter chief business officer applied genetic technologies corporation t   spotteragtccom read at biospacecom related news agtc agtc and the medical college of wisconsin announce publication of natural history study data evaluating residual photoreceptor cone status in patients with cngbassociated achromatopsia life sciences symposium lands pharma bro martin shkreli for program lineup agtc agtc ceo aims to grow headcount at kendall square office former celgene celg chief exec joins sorrento srne as chief medical officer and president of clinical development agtc agtc sets up shop in florida new facility to house  employees  ceos with the biggest golden parachutes in life science agtc agtc announces presentations in upcoming scientific conferences life science ceos and their rosy predictions of the future agtc agtc to present at the cantor fitzgerald second annual healthcare conference on july   bring harambe back pharma bro martin shkreli says he’s trying to please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • agtc   • biotechpharma  personnel                 anne m vanlent  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in anne m vanlent board member at aviragen therapeutics inc view full profile are you anne m vanlent claim your profile   sign up for equilar atlas and view anne m vanlents full profile with equilar atlas you can identify corporate executives in anne m vanlents network and community follow changes in anne m vanlents employment and moneyinmotion connect with anne m vanlent through your network of contacts anne m vanlents executive work history current board member agtc board member novelion therapeutics inc board member aviragen therapeutics inc past to view anne m vanlents complete executive work history sign up now age      anne m vanlents biography anne m vanlent has served as one of our directors since march  ms vanlent is currently the president of amv advisors a company which she founded in may  to provide corporate strategy and financial consulting services to emerging growth life sciences companies from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a company that developed and marketed prescription dermatology products that was publiclytraded before being acquired by stiefel laboratories in august  from july  to october  she was the executive vice presidentportfolio m  read more anne m vanlent has served as one of our directors since march  ms vanlent is currently the president of amv advisors a company which she founded in may  to provide corporate strategy and financial consulting services to emerging growth life sciences companies from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a company that developed and marketed prescription dermatology products that was publiclytraded before being acquired by stiefel laboratories in august  from july  to october  she was the executive vice presidentportfolio management for sarnoff corporation a multidisciplinary research and development firm from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company ms vanlent also currently serves as lead independent director of chair of the audit committee of and a member of the nominating and corporate governance committee of aviragen therapeutics inc nasdaqavir and as a director of and chair of the audit committee of advanced genetic technologies corporation nasdaqagtc and as a director of and a member of the compliance committee and audit committees of novelion therapeutics inc nasdaqnvln novelion was recently formed from the merger of qlt inc nasdaqqlti and aegerion pharmaceuticals inc nasdaqaegr where she served as a director chair of the audit committee and member of the compliance committee within the past five years ms vanlent formerly served on the board of directors of integra life sciences holding corporation nasdaqiart and onconova therapeutics inc nasdqaontx ms vanlent received a ba degree in physics from mount holyoke college we believe that ms vanlents significant management experience in both public and private life sciences companies as well as expertise in financial and accounting matters make her a valuable member of our board of directors and enable her to serve as our audit committee financial expert source ocera therapeutics inc on    sign up for equilar atlas and view anne m vanlents full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like anne m vanlent more specifically youll be able to identify corporate executives in anne m vanlents network and community follow changes in anne m vanlents employment and moneyinmotion connect with anne m vanlent through your network of conections view full profile   search for over  executive profiles bio example anne m vanlent anne m vanlents connections  sign up now to view anne m vanlents  connections » stephen d chubb board member charles river laboratories international inc jerry e corbin vice president and corporate controller integra lifesciences holdings corporation raymond g murphy board member integra lifesciences holdings corporation joseph m patti dir president and chief executive officer aviragen therapeutics inc john h mooradian corporate vice president global operations and supply chain integra lifesciences holdings corporation robert t davis corporate vice president and president orthopedics and tissue technologies integra lifesciences holdings corporation russell h plumb former executive chairman and principal financial officer aviragen therapeutics inc daniel l reuvers corporate vice president and president specialty surgical solutions integra lifesciences holdings corporation brian m larkin board member dynatronics corp thomas j baltimore chairman of the board president and chief executive officer park hotels  resorts inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith elon r musk ceo and chairman tesla david j oconnor president and ceo the madison square garden company claiborne p deming chairman of the board murphy oil corporation × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   anne vanlent  integra lifesciences corporation  zoominfocom anne m vanlent executive profile  biography  bloomberg july    pm et pharmaceuticals company overview of ocera therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile anne m vanlent independent director ocera therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background ms anne m vanlent founded amv advisors in  and serves as its president ms vanlent served as the president of amv associates from march  to august  she served as chief financial officer and senior vice president of the liposome company inc from  to  and also served as its executive she served as an executive vice president and treasurer of barrier therapeutics inc from may  to april   she served as chief financial officer and  executive vice president of trophix pharmaceuticals inc she served as the chief financial officer of barrier therapeutics inc from may  to april   and also served as its principal accounting officer she served as an executive vice president of portfolio management at sarnoff corporation she has been a director of applied genetic technologies corporation since august   ms vanlent has been an independent director at aviragen therapeutics inc biota pharmaceuticals inc since may  and has been its lead director since november  she served as a director of novelion therapeutics inc from november   to june   she served as a director at aegerion pharmaceuticals inc from april   to november   she has been independent director at ocera therapeutics inc since march  she serves as a director of a private fuel cell development company she served as a director of onconova therapeutics inc from july   to may   she served as a director of evue inc and tranzyme pharma inc ms vanlent served as a director of integra lifesciences holdings corporation from december   to may   tranzyme inc since march  istat corp since july  and penwest pharmaceuticals co from december  to  ms vanlent received a ba in physics from mount holyoke college and did graduate work in biophysicsread full background corporate headquarters  university avenuepalo alto california united statesphone fax  board members memberships directorevue incpresentdirectorpenwest pharmaceuticals copresentindependent directorocera therapeutics incpresentlead directoraviragen therapeutics incpresentdirectorapplied genetic technologies corporation education ba mount holyoke college other affiliations integra lifesciences holdings corporationthe liposome company incsarnoff corporationnovelion therapeutics incistat corppenwest pharmaceuticals coonconova therapeutics incaviragen therapeutics inctrophix pharmaceuticals incevue incbarrier therapeutics inctranzyme incmount holyoke collegeapplied genetic technologies corporationtranzyme pharma incaegerion pharmaceuticals inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ocera therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close board of directors agtc youtube linkedin facebook twitter board of directors led by the best scott koenig dr koenig has been president and chief executive officer of macrogenics sinceseptember   he is chairman of the board of directors at applied genetic technologies corporation agtc and at the children’s research institute cri of children’s national medical center and serves as a board member of macrogenics the biotechnology industry organization bio children’s national medical center and is a member of the cornell university council  prior to joining macrogenics he served as senior vice president of research at medimmune inc where he participated in the selection and maturation of the companys product pipeline for  years from  to  he worked in the laboratory of immunoregulation at the national institute of allergy and infectious diseases niaid at the national institutes of health nih where he investigated the immune response to retroviruses and studied the pathogenesis of aids dr koenig received his ab and phd from cornell university and his md from the university of texas health science center in houston where he was elected to alpha omega alpha  he completed his residency in internal medicine at the hospital of the university of pennsylvania and is board certified in internal medicine and allergy and immunology david guyer dr guyer is cofounder chief executive officer and chairman of the board of ophthotech corporation he has significant medical drug development and commercial experience in ophthalmology prior to joining ophthotech dr guyer worked as a venture capitalist and partner at sv life sciences following a successful career in academic medicine as professor and chairman of the department of ophthalmology at new york university school of medicine dr guyer cofounded and served as ceo and director at eyetech pharmaceuticals inc where he led the company through private public and corporate financings over  million including a  million ipo offering he has served on the board of directors for many public and private companies dr guyer graduated summa cum laude from yale college receiving his bachelor of science degree and earned his medical degree from the johns hopkins university school of medicine he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school ed hurwitz ed is a director with alta partners and managing director of precision bioventures llc  in addition to agtc he currently serves on the board of directors of macrogenics and viewpoint therapeutics  ed also led alta’s investments in avid radiopharmaceuticals calistoga pharmaceuticals cara therapeutics  chemocentryx foldrx pharmaceuticals sunesis pharmaceuticals taligen therapeutics threshold pharmaceuticals and zafgen prior to joining alta ed served as senior vice president and cfo of affymetrix from  to  from  to  ed was a biotechnology research analyst for robertson stephens  company and from  to  was a biotechnology research analyst for smith barney shearson from  to  ed practiced commercial law at cooley godward llp ed earned his juris doctor and master of business administration degrees in  from the university of california berkeley’s boalt school of law and haas school of business respectively ed earned a bachelor of arts in molecular biology from cornell university in  ivana magovcevicliebisch dr magovcevicliebisch joined teva as senior vice president head of global business development in april  in this capacity she is responsible for the execution of transactions identified by teva’s rd global franchises and us specialty teams including the licensing andor acquisition of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch joined dyax corp in april  and had served as an executive officer at the company since  during her tenure she held several senior positions within the company most recently as executive vice president and chief operating officer prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma dr magovcevicliebisch received her juris doctor in high technology law from suffolk university law school boston ma and her doctor of philosophy in genetics from harvard university cambridge ma arnie oronsky dr arnold l oronsky has been a general partner at interwest since  he was formerly vice president for discovery research for the lederle laboratories division of american cyanamid company where he directed all of the research for new drugs and supervised approximately three hundred employees dr oronsky holds a phd in immunology from columbia university and has published over  scientific articles in addition to being a senior partner at interwest he also serves as a senior lecturer in the department of medicine at johns hopkins medical school dr oronsky serves as a director on the boards of several life science corporations anne vanlent anne m vanlent is currently the president of amv advisors an advisory firm which she founded in  to provide corporate strategy and financial consulting services to emerging growth life sciences companies she currently serves as a director of and chair of the audit committee of ocera therapeutics inc a director member of the audit committee and member of the compliance committee of novelion pharmaceuticals inc previously aegerion pharmaceuticals inc   and as lead independent director and audit chair of aviragen pharmaceuticals inc formerly biota all nasdaq listed companies  from may  through april  ms vanlent was the executive vice president and chief financial officer of barrier therapeutics inc a nasdaq company that developed and marketed prescription dermatology products that was acquired by stiefel laboratories in august  from july  to october  she was the executive vice president – portfolio management for sarnoff corporation a multidisciplinary research and development firm  from  to  she served as the senior vice president and chief financial officer of the liposome company inc a publiclytraded biopharmaceutical company she served as a director chair of the audit committee and member of the compensation committee of onconova therapeutics from july  to may  and as director of integra life sciences holding corporation nasdaqgs iart from  to may  and chaired its audit committee from  until  she also served as a director and chair of the audit committee of penwest pharmaceuticals a nasdaqlisted company from  through its sale to endo pharmaceuticals inc in the fall of   ms vanlent received a ba degree in physics from mount holyoke college   james rosen jimmy rosen is a partner on intersouth’s life sciences investment team  he began with the firm as an intern in  while pursuing his graduate degrees joined fulltime in  and became a partner in   prior to joining intersouth he spent  years in clinical research and financial positions in the health care and biotechnology sectors jimmy’s research experience includes programs at the lineberger comprehensive cancer center at uncchapel hill the national cancer institute duke university medical center and its comprehensive cancer center  he also managed and monitored clinical trials at a privately held contract research organization which led to fdaapproved products  jimmy spent several years as an equity research analyst at brean murray  co covering biopharmaceuticals genomics generics drug delivery and medical device companies  prior to his research and wall street functions he spent five years in emergency medical services as a mountain search  rescue and ambulance medic jimmy currently serves on numerous boards and advisory committees including the public health foundation board and dean’s advisory council for the gillings school of global public health at the university of north carolina the board of visitors for north carolina central university the board of florida bio and the oversight committee for the dukecoulter translational partners program  he is also a frequent lecturer at duke unc and nc state university jimmy holds a ba from duke university and an mba from uncchapel hill’s kenanflagler school of business where he was a carolina venture fellow and recipient of the frank hawkins kenan award for excellence  he received his msph from the unc school of public health where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment  in  jimmy was awarded the eisenhower fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in china and southeast asia sue washer an experienced entrepreneur with a strong scientific and operational background sue brings a decade of experience in pharmaceutical management and research with abbott labs and eli lilly  company and more than  years of senior management experience with entrepreneurial firms in florida including three startups at agtc sue has successfully secured investments of more than  million from nationally recognized venture capitalists and granting agencies negotiated and closed on a major collaboration with a top five biotech company lead the company to complete critical milestones and recruited an experienced management team her experience as a group leader with abbott’s diagnostic division helped hone her skills in bringing new products and technologies from the lab bench into the market place sue sits on the board of the university of florida’s center for entrepreneurship bioflorida southeast bio gainesville area chamber of commerce gainesville area innovation network and the florida high tech corridor council she has a degree in biochemistry from michigan state university and an mba from the university of florida where she was one of the first graduates from the warrington college of business entrepreneurship program about us our teamboard of directors scientific advisors  foundersophthalmology scientific advisory boardotology scientific advisory board careers and internships contact us alachua – headquarters  nw th terrace suite  alachua florida   map cambridge one kendall square w suite b cambridge ma   map name  email  comments or questions security code please enter the letters from the image below in order to prevent spam  copyright     agtc    social media disclaimer  facebook facebook   ？ facebook ？？：？，。english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook